Single vs Multi-fraction SRS Patients on Immunotherapy (MIGRAINE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04427228|
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : September 16, 2021
|Condition or disease||Intervention/treatment||Phase|
|Brain Cancer Brain Metastases||Radiation: Radiosurgery Single Treatment Radiation: Radiosurgery Three Treatments||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||74 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||MIGRAINE: Randomized trIal of Single Versus Multifraction Radiosurgery on Immunotherapy|
|Actual Study Start Date :||June 29, 2020|
|Estimated Primary Completion Date :||July 10, 2023|
|Estimated Study Completion Date :||July 10, 2025|
|Experimental: Arm A||
Radiation: Radiosurgery Three Treatments
Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
Other Name: SRS
|Active Comparator: ARM B||
Radiation: Radiosurgery Single Treatment
Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) < 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
Other Name: SRS
- Multi-Fraction SRS superiority compared to single fraction SRS [ Time Frame: 4 years ]To determine if Multi-Fraction SRS will decrease the rate of radionecrosis when compared to single-fraction SRS for patients with small metastases and are on immunotherapy.
- Target metastasis progression [ Time Frame: 4 years ]Target metastasis progression will be assessed using adapted Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) consensus imaging criteria. In brief, progressive disease is defined as a ≥20% relative increase in the longest diameter (LD) of the target metastasis compared to its smallest LD recorded on study, with a minimum absolute increase of 5 mm
- Overall Survival Rate [ Time Frame: 4 years ]Time from randomization to death
- Acute CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities [ Time Frame: 4 years ]Any acute CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities, within 90 days of SRS completion (toxicity must be specified).
- Late CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities [ Time Frame: 4 years ]Any late CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities, greater than 90 days from SRS completion (toxicity must be specified).
- rate of individual metastases radionecrosis [ Time Frame: 4 years ]To compare the rates over time of individual metastases radionecrosis using a parametric survival analysis
- rate of individual metastases rates of edema [ Time Frame: 4 years ]To compare rates over time of individual metastases rates of edema using a parametric survival analysis.
- Rates of Symptomatic Edema [ Time Frame: 1 year ]To compare rates of symptomatic edema at 3 months, 6 months, and 1 year.1
- Time to any distant intracranial failure [ Time Frame: 4 years ]Time to any distant intracranial failure (ie, appearance of brain metastasis at untreated site).
- Time to initiation of any combination [ Time Frame: 4 years ]Time to initiation of any combination of death, salvage SRS, WBRT, or neurosurgical resection for intracranial failure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04427228
|Contact: Benjamin Onderdonk, MDfirstname.lastname@example.org|
|United States, Illinois|
|University Of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Benjamin Onderdonk, MD 773-702-6870 email@example.com|
|Principal Investigator: Steven Chmura, MD|
|Sub-Investigator: Benjamin Onderdonk, MD|
|Principal Investigator:||Steven Chmura, MD||University of Chicago|